ERBB2 and breast carcinoma: We selected the biomarkers with the most frequently used and the most significant indicators in therapeutic decisions of breast cancers [21], so that estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2), progesterone receptor (PR), and Ki-67 were chosen and thereby four straight reaction channels were designed.